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Abstract 
Background:  Subarachnoid hemorrhage (SAH) is a neurological disease where the majority of the patients are criti‑
cally ill. The adipokine leptin has in cerebral emergencies been related to severity of disease and to adverse outcome. 
The aim of this study was to examine leptin levels over time after SAH and associations to gender, age, body mass 
index, severity of disease, parenteral lipids, systemic organ failure and outcome.
Methods: Prospective observational study in 56 patients. Leptin was obtained 0–240 h after SAH, in 48 h intervals. 
Severity of disease was assessed with the Hunt and Hess score, organ failure with the sequential organ failure assess‑
ment score, and outcome with Glasgow outcome scale. Leptin levels in the SAH group were compared with controls 
from the same geographical area.
Results: At admission, Leptin was significantly higher in SAH patients compared to controls, both in female 
(28.6 ± 25.6 vs 13.0 ± 2.3 ng/mL, p = 0.001) and male patients (13.3 ± 8.4 vs 4.3 ± 0.7 ng/mL, p = 0.001). Leptin lev‑
els remained stable over time. Female patients had significantly higher leptin levels than male patients, and deceased 
female patients had higher leptin levels than female survivors (85.5 ± 20.5 vs 50.5 ± 34.6, n = 4/35, p < 0.05). Leptin 
levels did not differ between male survivors and non‑survivors. Leptin levels were not associated with severity of 
disease, organ failure or parenteral lipids.
Conclusion: Leptin levels were significantly higher in both male and female patients compared to controls. Higher 
leptin levels were related to outcome and organ failure in women but not in men. When analysing leptin levels 
gender‑related differences should be considered.
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Background
Subarachnoid haemorrhage (SAH) caused by the rup-
ture of a cerebral aneurysm is a serious form of stroke, 
where a majority of the patients are initially critically ill 
(Diringer et al. 2011). The SAH produces an initial global 
ischemic brain injury that stimulates the sympathetic 
nervous system and starts an inflammatory process (Zet-
terling et al. 2010; Naredi et al. 2000).
This inflammatory process not only affects the brain 
but also gives rise to a systemic inflammatory response 
syndrome (SIRS), with release of inflammatory mediators 
such as cytokines and adipokines from adipocytes (Harle 
and Straub 2006).
In critical illness, the adipose tissue has gone from 
being just storage of energy to become an active organ 
taking part in the inflammatory process (Marques and 
Langouche 2013).
The adipokine leptin is a 16  kDa large protein that is 
mainly produced by the white adipose tissue and regu-
lates energy balance (Zhang et  al. 1994). Food depriva-
tion and fasting decrease circulating leptin levels whereas 
food intake increases leptin levels (Gosmanov et al. 2010; 
Garcia-Lorda et  al. 2003; Evans et  al. 2001). Leptin also 
acts as a cytokine and is as such a regulator of innate 
immunity (Zhang et al. 1994; Schwartz et al. 2000). Lep-
tin levels are higher in women than in men, and circulat-
ing levels strongly associates with fat mass, measured for 
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example as body mass index (BMI). Leptin has a cyclic 
secretion and normally peaks at night, but the circadian 
rhythm has been reported as lost during critical illness 
(Bornstein et al. 1998; Simon et al. 1998). Studies in criti-
cally ill patients have shown variations in leptin levels 
and both normal and elevated leptin levels have been 
reported to correlate to inflammatory markers, body 
temperature and cortisol levels (Bornstein et  al. 1998; 
Papathanassoglou et al. 2001; Koch et al. 2010; Chen et al. 
2014; Grigoras et al. 2014; Yousef et al. 2010).
Leptin-receptors have been located to several parts 
of the central nervous system (CNS), most abundant in 
hypothalamus but also in the brainstem (Schwartz et al. 
2000; Grill and Hayes 2012). Increased leptin levels have 
been reported in patients with intracerebral haematomas 
(ICH), SAH and ischemic stroke. Further, elevated lep-
tin levels have been shown to predict both ischemic and 
haemorrhagic stroke (Soderberg et  al. 2004; Kim et  al. 
2012; Kantorova et  al. 2011; Dong et  al. 2010; Du et  al. 
2013; Fan et al. 2013; Huang et al. 2014; Zhang et al. 2007; 
Zhao et al. 2012).
The aim of this study was to examine if leptin lev-
els change over time in the acute phase of SAH and if 
the leptin levels were associated with gender, age, BMI, 
severity of disease, administration of parenteral lipids, 
systemic organ failure and outcome.
Patients and methods
This is a prospective observational study of patients with 
SAH due to a ruptured cerebral aneurysm. The patients 
were treated at the department of neurosurgery, Umeå 
University hospital (UUH), Sweden and were consecu-
tively included from March 2008 until September 2009. 
The department of neurosurgery provides neurosurgical 
care to the four northernmost counties in Sweden with a 
total of 878,000 inhabitants (in 2008).
Inclusion criteria were; SAH caused by a cerebral aneu-
rysm, verified by digital subtraction angiography (DSA) 
or CT angiography (CTA), age ≥ 18 years, and arrival at 
UUH ≤ 48 h after the first symptom of SAH that brought 
the patient to hospital. Exclusion criteria were; pregnant/
lactating woman, earlier SAH or intracranial surgery.
At admission to UUH, a medical history was obtained 
regarding co-morbidities and medication. The length and 
weight of the patient was noted and BMI was calculated. 
BMI >25 was considered as overweight.
The severity of the SAH was assessed with the Hunt–
Hess (H&H) score. H&H extends from 1; minimal 
symptoms, to 5; deep coma. H&H 3–5 is considered as 
a severe clinical condition and H&H 1–2 as a less severe 
clinical condition (Hunt and Hess 1968). The H&H scores 
were obtained from the first clinical examination made 
by a physician.
Sequential Organ Failure Assessment (SOFA) score was 
used for assessment of organ failure. SOFA extends from 
zero; no organ failure, to four; pronounced organ failure. 
SOFA is based on observations during a 24-h interval and 
the most abnormal value from the preceding 24 h is used. 
Six different organs are evaluated; respiration, hematol-
ogy, hepatic, cardiovascular, renal and central nervous 
system (CNS) (Vincent et al. 1996). SOFA CNS was not 
used in this study, since a majority of the patients were 
sedated at some time during the study period. A daily 
total SOFA score (SOFAsum) was calculated including all 
organ systems except CNS. In order to find out whether 
severe organ failure was related to leptin levels, patients 
were divided in two groups;
1. Severe organ failure; SOFA ≥ 3 in at least one organ 
system at any time during the study period.
2. No severe organ failure; SOFA < 3 at all times, in all 
organ systems, during the study period.
Leptin
The first sample for leptin analysis was obtained at 
admission within 0–48  h from the first symptoms of 
SAH. Consequent samples were thereafter obtained in 
48  h intervals i.e. in the time intervals: 49–96, 97–144, 
145–192, 193–240 h after the SAH. Blood sampling was 
performed between 8 and 11 AM. Leptin levels at admis-
sion were compared to levels in a control population 
from the same area in northern Sweden. This control 
group emerged from the Northern Sweden MONICA 
survey (MONItoring of trends and determinants in Car-
diovascular disease) (Eriksson et al. 2011).
A double-antibody radioimmunoassay from Mil-
lipore Linco, St. Charles, MO, USA, was used for both 
SAH patients and the control population, and the total 
coefficient of variation for leptin was 4.7  % at both low 
(2–4 ng/mL) and high (10–15 ng/mL) levels (Lilja et  al. 
2010).
Treatment protocol
A local treatment protocol for SAH was used, coherent 
in its key parts with strategies given by the Neurocriti-
cal Care Society’s Multidisciplinary Consensus Confer-
ence and American Heart Association (AHA) guidelines 
(Diringer et  al. 2011; Connolly et  al. 2012). The pro-
tocol includes normoventilation, normovolemia and 
keeping sodium, glucose, haemoglobin and albumin 
within normal limits. The intention was to secure the 
cerebral aneurysms within 24  h after arrival, either by 
surgical or endovascular treatment. Early enteral nutri-
tion was encouraged and was started as early as within 
the first 48  h after admission. Parenteral nutrition was 
administered using StructoKabiven®, a mix of glucose, 
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amino acids and lipids (Fresenius Kabi 2015). The lipids 
in StructoKabiven® is based on StructoLipid® emul-
sion containing an interesterified mixture of equimolar 
amounts of long chain triglycerides (LCT) from soybean 
oil and medium chain triglycerides synthetically derived 
from a mixture of coconut and/or palm kernel oil (MCT). 
The equimolar relation between MCT and LCT trans-
lates to 34 % (V/V) and 66 % (v/v), respectively (Fresenius 
Kabi, Uppsala, Sweden).
General anaesthesia was performed with thiopental, 
sevoflurane and remifentanil. In ventilated patients at 
the intensive care unit the most commonly used seda-
tive agent was propofol. Propofol is an intravenous 
anaesthetic agent dissolved in Intralipid® (McKeage and 
Perry 2003). The propofol preparation from the manu-
facturers contains, in addition to 10 or 20 mg/mL propo-
fol, soybean-oil (100  mg/mL), egg yolk phospholipids 
(12 mg/mL), glycerol (22.5 mg/mL), and sodium edetate 
(0.055 mg/mL). In case of prolonged controlled ventila-
tion due to neurological or respiratory needs a change 
from propofol to midazolam was usually made. Thiopen-
tal was added in patients with intracranial hypertension, 
Fentanyl was given in continuous infusion for analgesia. 
All patients were treated with intravenous nimodipine 
(0.2  mg/mL dissolved in ethanol (96  %) with additives 
of macrogol 4000, sodium citrate and citric acid (Nimo-
top®, Bayer). The dose administered aimed at 10  mL/h. 
Patients in need for prolonged sedation and ventilation 
had continuous intracranial pressure monitoring with an 
external ventricular drain or an intraparenchymal sen-
sor (Codman® MicroSensor™, Codman & Shurtleff Inc. 
Raynham, MA, USA).
At a follow-up visit performed approximately 1  year 
after the SAH, an independent research nurse scored 
the patients according to Glasgow outcome scale (GOS) 
by structured interviews (Jennett and Bond 1975). GOS 
extends from 1; dead to 5; good recovery. Favorable out-
come was defined as GOS 4–5 and unfavorable outcome 
as GOS 1–3.
Statistics
The statistical software package, Prism, version 5.0 
(GraphPad Software Inc., CA, USA) was used for statisti-
cal analyses. Data are presented as mean ± SD, median 
(range) or percentage. The non-parametric Mann–Whit-
ney test was used for comparison of leptin and different 
clinical parameters. Wilcoxon-signed-rank-test was used 
for comparison of leptin levels at admission with differ-
ent time points and before/after administration of lipids. 
Fisher’s exact test was used for differences in SOFA score 
between female and male patients. Spearman’s test was 
used for correlation of leptin levels and and SOFA score. 
Statistical significance was set at p < 0.05.
Results
Fifty-six patients were included in the study, 39 female 
(70 %) and 17 male (30 %) patients, and median ages were 
59 (31–82) years in female and 63 (26–77) years in male 
patients.
In total, 259 samples of leptin were obtained within the 
first 240 h after the SAH, in average 5 (2–5) samples per 
patient. Leptin levels did not change significantly com-
pared to admission (0–48 h) over time (49–240 h) after 
the SAH, neither in male nor in female patients. Male 
patients had significantly lower leptin levels compared to 
female patients 0–192 h after SAH (Fig. 1).
Leptin at admission was significantly higher in SAH 
patients, compared to controls from the Northern Swe-
den MONICA health study, both in female (28.6 ± 25.6 
vs 13.0  ±  2.3  ng/mL, p  =  0.001) and in male patients 
(13.3 ± 8.4 vs 4.3 ± 0.7 ng/mL, p = 0.001).
Leptin values at admission in relation to different clini-
cal parameters are given in Table 1. Peak and nadir leptin 
values in each patient 0–240  h after SAH in relation to 
different parameters are given in Table 2.
In 22 female and in 12 male patients, leptin levels 
before and after start of intravenous lipid emulsion 
administration, as part of parenteral nutrition and/or 
sedation with propofol, were analysed. There was no sig-
nificant difference between leptin levels before, and 48 h 















































Fig. 1 Leptin (ng/mL) in female and male patients at different 
time intervals, 0–240 h after subarachnoid haemorrhage (SAH) F 
female patients (white bars), M male patients (grey bars). *Signifi‑
cant difference p < 0.05. Leptin values at admission, 0–48 h, after 
SAH and thereafter distributed into 48 h intervals: 49–96, 97–144, 
145–192, 193–240 h after SAH. Male patients: 0–48 h: n = 17, 49–96 h: 
n = 17, 97–144 h: n = 16, 145–192 h: n = 16, 193–240 h: n = 16. 
Female patients: 0–48 h: n = 37, 49–96 h: n = 37, 97–144 h: n = 35, 
145–192 h: n = 34, 193–240 h: n = 34. Dotted lines normal values for 
males: 4.3 ± 0.7 ng/mL/females: 13.0 ± 2.3 ng/mL
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(36.0 ± 27.3 vs 36.8 ± 25.1 ng/mL) nor in male patients 
(12.7 ± 9.6/15.2 ± 8.8 ng/mL) (Fig. 2).
Patients with severe organ failure (SOFA ≥ 3) in at least 
one organ system at any time during the study period 
or patients without severe organ failure (SOFA score 
<3) in all organ systems during the study period is given 
in Table  3. The only difference found between female 
and male patients was a significantly higher incidence 
of circulatory failure in women at 49–144  h after SAH 
(Table 3).
There was a correlation between SOFAsum and leptin 
obtained during the same 24 h interval in female (Spear-
man’s r  =  0.25, CI (0.10–0.39), p  =  0.0007) but not in 
male patients (Fig. 3).
Seven patients died during the study period (4 female 
and 3 male patients), median time to death was 20 (9–39) 
days. GOS 1–3 (unfavourable outcome) was found in 
15/56 (27 %) patients and GOS 4–5 (favourable outcome) 
was found in 41/56 (73  %) patients, Fig.  4. Deceased 
female patients had both significantly higher leptin lev-
els at admission and higher peak and nadir leptin levels 
during the study period than female survivors. In male 
patients, leptin levels did not differ between survivors 
and non-survivors (Tables 1, 2).
A follow-up visit was performed median 13 (6 ±  24) 
months after the SAH.
Discussion
Compared to male patients, female SAH patients had sig-
nificantly higher leptin values at admission and during 
the first 192 h after the SAH. This is not surprising since 
the levels of leptin are normally significantly higher in 
females compared to males, even when leptin is corrected 
for differences in BMI (Rosenbaum et al. 1996). This dif-
ference in gender has been observed already during 
childhood, and is actually starting already at birth (Waut-
ers et  al. 2000). When dividing the patients at median 
Table 1 Leptin (ng/mL) at admission (0–48 h) after SAH
In two female patients, blood samples from 0 to 48 h are not obtained
a Median age in female patients was 59 (31–82) and in male patients 63 (26–77) 
years
b BMI body mass index; females patients median 24 (18–44), male patients 
median 25 (22–30)
c Patients with pharmacologically treated hypertension at admission
d H&H Hunt and Hess score for classifying the severity of the SAH; 1 
asymptomatic/minimal headache; 2 moderate/severe headache, no 
neurological deficit other than cranial nerve palsy; 3 drowsiness, confusion 
or mild focal deficit; 4 stupor, moderate to severe hemiparesis; 5 deep coma, 
moribund appearance. H&H 1–2 = less severe clinical condition, H&H = 3–5 
severe clinical condition
e GOS Glasgow outcome scale. (1) Dead, (2) Vegetative state, (3) Severe 
disability, (4) Moderate disability, (5) Good recovery. GOS 1–3 = Unfavourable 
outcome, GOS 4–5 = favourable outcome
f Seven patients died during the study period, three males and four females. 
Median time to death was 20 (9–39) days
g Sequential Organ Failure Assessment (SOFA) scores organ failure from zero; 
no organ failure, to four; pronounced organ failure. Six different organ systems 
are scored; respiration, haematology, hepatic, cardiovascular, renal and central 
nervous system (CNS). The worst value obtained during a 24-h period is used. 
In this study the SOFA CNS score was not used, Patients were divided in; severe 






 Female/male 37/17 35.5 ± 25.5/14.4 ± 7.8 <0.0001
Agea
 Female
  ≤59/>59 18/19 23.8 ± 16.9/46.5 ± 27.6 ns
 Male
  ≤63/>63 8/9 15.6 ± 10.4/11.3 ± 6.1 ns
BMIb
 Female
  ≤25/>25 20/17 27.7 ± 19.4/28.3 ± 2.9 <0.05
 Male
  ≤25/>25 11/6 24.5 ± 16.4/26.9 ± 1.6 ns
Hypertensionc
 Female
  Yes/no 10/27 33.1 ± 18.0/36.3 ± 28.0 ns
 Male
  Yes/no 8/9 17.8 ± 9.7/9.3 ± 4.6 <0.05
Hunt and Hessd
 Female
  1–2/3–5 17/20 38.9 ± 29.1/32.6 ± 22.2 ns
 Male
  1–2/3–5 12/5 12.7 ± 9.2/14.8 ± 6.7 ns
GOSe
 Female
  1–3/4–5 8/29 46.7 ± 33.9/32.4 ± 22.4 ns
 Male
  1–3/4–5 6/11 17.7 ± 11.6/10.9 ± 5.3 ns
Deceasedf
 Female
  Yes/no 4/33 44.6 ± 33.5/31.9 ± 22.5 <0.05
 Male






  0–2/3–4 11/26 39.0 ± 28.2/34.0 ± 24.7 ns
 Male
  0–2/3–4 4/13 12.9 ± 5.2/13.4 ± 9.4 ns
Table 1 continued
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Table 2 Peak and mean Nadir values of leptin (ng/mL) 0–240 h after SAH
Peak leptin value and nadir leptin value in each patient 0–240 h after SAH
F female patient, M male patient
a Median age in females was 59(31–82) years and in males 63(26–77) years
b BMI Body mass index, females median 24 (18–44), males median 25 (22–30)
c Pharmacologically treated hypertension
d H&H Hunt and Hess is scale for classifying the severity of the SAH; 1 asymptomatic/minimal headache; 2 moderate/severe headache, no neurological deficit other 
than cranial nerve palsy; 3 drowsiness, confusion or mild focal deficit; 4 stupor, moderate to severe hemiparesis; 5 deep coma, moribund appearance. H&H 1–2 = less 
severe clinical condition, H&H = 3–5 severe clinical condition
e GOS Glasgow outcome scale. (1) Dead, (2) Vegetative state, (3) Severe disability, (4) Moderate disability, (5) Good recovery. GOS 1–3 = Unfavourable outcome, GOS 
4–5 = favourable outcome
f Seven patients died during the study period, three males and four females. Median time to death was 20 days (9–39)
g Sequential Organ Failure Assessment (SOFA) scores organ failure from zero; no organ failure, to four; pronounced organ failure. Six different organ systems are 
scored; respiration, haematology, hepatic, cardiovascular, renal and central nervous system (CNS). The worst value obtained during a 24-h period is used. In this study 
the SOFA CNS score was not used, Patients were divided in; severe organ failure ≥3 and no severe organ failure 0–2 at any time during the period studied
Parameter Number of samples Peak leptin (ng/mL) Sig. Nadir leptin (ng/mL) Sig.
Gender
 F/M (39/17) 54.1 ± 35.0/28.9 ± 23.7 ns 21.7 ± 16.0/9.3 ± 6.3 <0.001
Agea
 Female
  ≤59/>59 (18/21) 53.6 ± 42.0/54.4 ± 28.6 ns 18.8 ± 14.2/24.2 ± 17.3 ns
 Male
  ≤63/>63 (10/7) 36.3 ± 28.5/18.3 ± 7.8 ns 10.8 ± 7.4/7.1 ± 3.5 ns
BMIb
 Female
  ≤25/>25 (23/16 41.3 ± 27.8/72.3 ± 36.8 <0.05 14.5 ± 8.8/32.0 ± 18.4 <0.001
 Male
  ≤25/>25 (11/6) 25.0 ± 23.1/36.0 ± 25.3 ns 7.8 ± 5.6/12.1 ± 6.9 ns
Hypertensionc
 Female
  Yes/no (11/28) 65.3 ± 38.3/49.6 ± 33.3 ns 25.5 ± 15.9/20.2 ± 16.1 ns
 Male
  Yes/no (8/9) 40.7 ± 30.2/18.4 ± 7.8 ns 12.4 ± 7.6/6.5 ± 3.1 ns
H&Hd
 Female
  1–2/3–4 (28/11) 51.0 ± 36.0/61.8 ± 32.5 ns 21.8 ± 17.5/21.4 ± 12.0 ns
 Male
  1–2/3–4 (12/5) 27.4 ± 20.2/32.6 ± 33.1 ns 9.3 ± 6.0/9.3 ± 7.6 ns
GOSe
 Female
  1–3/4–5 (9/30) 56.6 ± 34.7/53.3 ± 35.6 ns 26.8 ± 21.9/20.1 ± 13.9 ns
 Male
  1–3/4–5 (6/11) 34.4 ± 29.2/25.9 ± 21.1 ns 11.7 ± 8.8/8.0 ± 4.3 ns
Deceasedf
 Female
  Yes/No (4/35) 85.5 ± 20.5/50.5 ± 34.6 <0.05 38.1 ± 22.9/19.8 ± 14.3 <0.05
 Male
  Yes/no (3/14) 42.0 ± 42.7/26.1 ± 19.1 ns 12.1 ± 8.9/8.7 ± 5.8 ns
SOFAg
 Female
  0–2/3–4 (11/26) 49.1 ± 30.9/56.0 ± 36.8 ns 17.6 ± 9.7/23.3 ± 17.8 ns
 Male
  0–2/3–4 (8/9) 18.0 ± 10.1/38.5 ± 28.3 ns 8.0 ± 7.0/10.5 ± 5.6 ns




























Fig. 2 Leptin (ng/mL) before and 48 h after start of intravenous lipid infusion. Leptin in ng/mL. Female patients: Before; 36.0 ± 27.7 and after; 
36.8 ± 25.1 start of intravenous lipid infusion. n = 22 pairs, non‑significant. Male: Before: 12.7 ± 9.6 and after 15.2 ± 8.9 start of intravenous lipid 
infusion. n = 11 pairs, non‑significant




Leptin values in patients with a severe organ failure defined as SOFA ≥ 3 in at least one organ system at any time during the study period
Sequential Organ Failure Assessment (SOFA) scores organ failure from zero; no organ failure, to four; pronounced organ failure. Six different organ systems are scored; 
respiration, haematology, hepatic, cardiovascular, renal and central nervous system (CNS). The worst value obtained during a 24-h period is used. In this study the 
SOFA CNS score was not used















0–48 15/39 (38) 5/17 (29) ns 22/39 (56) 11/17 (65) ns 0 0 0
49–96 17/38 (45) 7/17 (41) ns 10/38 (26) 0 p < 0.0001 0 0 0
97–144 15/38 (39) 7/16 (44) ns 6/38 (16) 0 p < 0.0001 0 0 0
145–192 14/35 (40) 16/6 (38) ns 1/35 (3) 0 ns 0 0 0

































Fig. 3 Correlation between SOFAsum score and leptin levels. Sequential Organ Failure Assessment (SOFA) scores organ failure from zero; no organ 
failure, to four; pronounced organ failure. Six different organ systems are scored; respiration, haematology, hepatic, cardiovascular, renal and central 
nervous system (CNS). The worst value obtained during a 24‑h period is used. In this study the SOFA CNS score was not used. Every days SOFA are 
summarized = SOFAsum. The SOFA sum was correlated to the leptin value taken within the same 24 h interval during the study period of 0–240 h. a 
Female patients: Spearman’s r = 0.25, CI (0.10–0.39), p = 0.0007, n = 177 pairs. b Male patients. No correlation, CI (−0.1 to 0.3), p = 0.3, n = 82 pairs
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age, no difference related to age, could be found in SAH 
patients, although leptin levels are reported to decrease 
with age, independent of BMI, with a more pronounced 
decrease in women (Janeckova 2001). Leptin levels in 
SAH patients at admission were significantly elevated 
compared to controls, this is in accordance with other 
studies in critically ill patients and in patients with other 
acute cerebral diseases (Papathanassoglou et  al. 2001; 
Grigoras et al. 2014; Yousef et al. 2010; Fan et al. 2013). 
Severe respiratory and cardiovascular organ failure, 
defined as SOFA score ≥3 was observed in up to 45 % of 
the patients. No severe haematological, hepatic or renal 
organ failure was detected during the study period. Using 
SOFA score ≥3 as a marker for severe organ failure, no 
significant difference in leptin levels could be found in 
patients with or without severe organ failure in this study. 
In female patients, a correlation between the leptin value 
and the SOFA sum score could be found, indicating a 
gender dependent reaction to leptin in critical illness.
There was no significant change in leptin levels over 
time (0–240 h) after SAH, neither in female nor in male 
patients. Both decreasing and increasing leptin values in 
the acute phase (within 14 days) in critically ill patients 
have previously been reported (Papathanassoglou et  al. 
2001; Grigoras et  al. 2014; Yousef et  al. 2010). How-
ever, only one previous study has separated the results 
between male and female patients, finding higher leptin 
values in septic male patients (Chen et al. 2014). The dis-
tribution between male and female subjects in a study 
cohort may influence the result.
Several studies have investigated and found an asso-
ciation between elevated leptin levels and unfavourable 
outcome in cerebral emergencies such as ICH, ischemic 
stroke and SAH (Kim et  al. 2012; Dong et  al. 2010; Fan 
et al. 2013; Zhao et al. 2012; Zhang et al. 2013). Increased 
leptin levels have been found to be an independent pre-
dictor for mortality in ICH (Zhao et al. 2012; Zhang et al. 
2013). Elevated leptin levels in this study were not asso-
ciated with unfavourable outcome defined as GOS 1–3, 
neither in female nor in male patients. However, leptin 
levels were significantly higher in the four female patients 
who deceased compared to female survivors. This asso-
ciation with higher leptin levels in deceased patients was 
not found in male patients. Previous studies looking at 
leptin in relation to outcome have not analysed female 
and male patients separately, although it is well known 
that leptin levels are higher in females from early child-
hood (Kim et al. 2012; Dong et al. 2010; Fan et al. 2013; 
Zhao et al. 2012; Zhang et al. 2013).
The difference found in this study, with diverse patterns 
of reaction depending on gender, is intriguing and not 
easily understood. Different patterns depending on gen-
der have previously been reported in studies on stroke 
and diabetes, which may suggest that this is more than an 
accidental finding (Soderberg et al. 2004, 2007).
Experimental studies have shown that the brains of 
male and female rats are differently sensitive to the cat-
abolic actions of small doses of leptin (and insulin), and 
estrogens can alter the hypothalamic sensitivity for leptin 
(Clegg et al. 2003; Meli et al. 2004). Whether or not this 
is relevant for the associations of leptin described in this 
study is to our knowledge unknown. In addition, leptin 
may be a significant factor for sex-related differences in 
the development of inflammation and dysfibrinolysis in 
the vessel wall (Lloyd-Jones et al. 1999).
The leptin production after administration of intrave-
nous lipids is ambiguous and both decreased production 
of leptin and no change at all have been reported (Garcia-
Lorda et al. 2003; Evans et al. 2001; Marana et al. 2008). 
In this study we investigated leptin before and after 
administration of lipid containing parenteral nutrition 
or lipid containing propofol and no effect on leptin lev-
els were found before and after administration of lipids 
intravenously.
Even though leptin levels and regulation seem to be 
closely linked to both prediction and prognosis of cer-
ebrovascular diseases such as stroke and SAH, knowl-
edge about circulating levels of leptin has yet not found 
its clinical implication. However, our findings are in line 
with previous reports from our group suggesting that 
leptin does have an important role in vascular patho-
physiology in the brain and further mechanistic research 





















GOS 1 GOS 2-3 GOS 4-5
Fig. 4 Outcome assessed with Glasgow Outcome scale. The 
follow‑up was performed median 13 (6 ± 24) months after the SAH. 
GOS = Glasgow outcome scale. GOS 1–3 = Unfavourable outcome 
(GOS 1 = dead, GOS 2 = vegetative, GOS 3 = severe disability). 
GOS 4–5 = Favourable outcome (GOS 4 = moderate disability, GOS 
5 = Good outcome)
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Finally, the results from this study only apply to SAH 
patients.
Conclusion
Compared to controls, leptin levels were significantly 
higher in SAH patients at admission. Leptin levels were 
also significantly higher in female patients compared to 
male patients. Higher leptin levels were associated with 
increasing SOFA score, as a sign of increasing organ fail-
ure, in female but not in male patients. Female non-survi-
vors also had significantly higher leptin levels compared 
to female survivors. Differences in leptin levels related to 
organ failure and death were not found in male patients. 
The known difference in leptin levels between men and 
women has to be considered when results from studies 
are presented.
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